首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 593 毫秒
1.
为进一步证实正常免疫力小鼠6天SRC法的可行性,本实验旨在探讨与免疫缺陷小鼠(裸裸)SRC法有无区别。将同一人体肿瘤移植于裸鼠和正常小鼠肾包膜下,观察移植瘤生长、病理形态变化以及化疗药物的影响。结果表明,同一人体肿瘤移植于裸鼠和正常小鼠肾包膜下短期内生长具有相平行趋势。6次实验对比,其中裸鼠肾包膜下移物阳性生长率50%,正常小鼠肾包膜下移植物阳性生长率66.7%,显示两鼠SRC方法用于人体肿瘤药物敏感测定的可行性。采用裸鼠11天,正常小鼠6天法测试了3例人体肿瘤,分别对3种化疗药物(ADM、5-Fu、CTX)测定有明显的相关性。组织学检查证实均保持了原来人体肿瘤特征,对药物作用有明显的反应。  相似文献   

2.
小鼠肾包膜下移植法预测人胃癌、大肠癌对“胃瘤平”敏感性观察祝庆蕃,赵进英,务孔俊,凌雁(河南医科大学郑州450052)目前用于肿瘤对药物敏感性测试的方法有体内和体外法。1987年Bogden建立正常免疫小鼠肾包膜下移植人癌预测肿瘤对药物敏感性后,日益...  相似文献   

3.
目的研究岩消胶囊对小鼠肝癌的抑制作用。方法选取40只小鼠,随机分为空白对照组、阳性对照组、实验组,分别观察实体瘤重量、小鼠存活时间、实体瘤的形态学和对腹水癌细胞的直接杀伤死亡率。结果实验组的实体瘤重量显著降低(P〈0.01),抑瘤率达52.0%;小鼠存活时间明显延长,生命延长率81.6%(P〈0.01);对腹水癌细胞有显著的杀伤作用(P〈0.05)。结论岩消胶囊能显著抑制小鼠肝癌细胞移植性肿瘤的生长,减轻瘤体重量;能显著延长荷瘤小鼠生存期;同时对肿瘤细胞有直接杀伤作用。  相似文献   

4.
目的:建立小鼠EMT6乳腺癌移植瘤模型,观察霜蛎消结胶囊对小鼠EMT6乳腺癌移植瘤的抑制作用以及对p53和c-erbB-2表达的影响.方法:建立小鼠EMT6乳腺癌移植瘤模型,观察霜蛎消结胶囊对荷瘤小鼠免疫器官重量、小鼠移植性EMT6乳腺癌瘤重以及小鼠移植性EMT6乳腺癌p53和c-erbB-2表达的影响.结果:霜蛎消结胶囊的大、中、小3个剂量组与造模组比较,胸腺指数显著升高(P<0.05),霜蛎消结胶囊2.0 g/kg·bw和1.0 g/kg·bw剂量组均能明显抑制小鼠移植性EMT6瘤体的生长(P<0.05),霜蛎消结胶囊2.0 g/kg· bw剂量组和1.0 g/kg· bw剂量组织坏死面积明显大于对照组(P<0.05),实验组p53和c-erbB-2表达明显低于对照组(P<0.05).结论:霜蛎消结胶囊对小鼠移植性EMT6乳腺癌具有明显的抑制作用,其机理可能在于霜蛎消结胶囊可能起到下调突变型p53和c-erbB-2表达的作用,从而使肿瘤缩小,来发挥抗肿瘤作用.  相似文献   

5.
Chen Y  Xu Q  Wang L  Zhao G  Li S 《中国肺癌杂志》2001,4(1):29-32
目的 观察新城疫鸡瘟病毒及其HN基因与F基因对裸小鼠人肺腺癌移植瘤的抗肿瘤作用 ,并探讨其机制。方法 建立人肺腺癌细胞系在裸小鼠体内移植瘤动物模型 ,两组实验组瘤体内分别一次局部注射NDV病毒及携带HN及F基因的质粒 (pSV HN及pSV F)作抗肿瘤研究 ,同时设PBS对照。观察 5周 ,绘制肿瘤生长曲线 ,处死后量瘤重 ,并作电镜和光镜检查 ,观察其病理学改变。结果 NDV及其基因的质粒 (pSV HN及pSV F)对裸小鼠人肺腺癌移植瘤的生长有明显的抑制作用 (抑瘤率分别为 71.62 %和 79.40 % )。NDV组及质粒组与对照组瘤重均值之间差异显著 (P <0 .0 1)。对照组 14 %的肿瘤发生肝及肺的转移。NDV组电镜下可见肿瘤细胞内NDV粒子出芽。结论 NDV对裸小鼠人肺腺癌移植瘤有明显的抑瘤作用。pSV HN及pSV F亦明显的抑制裸小鼠人肺腺癌移植瘤生长 ,其抑瘤作用机制与NDV选择性地在肿瘤细胞内增殖并导致肿瘤细胞凋亡及溶解肿瘤细胞有关 ,由此推测在此过程中HN及F基因可能起主要作用。  相似文献   

6.
目的:观察IL-18对Lewis肺癌小鼠移植瘤生长的抑制作用。方法:建立Lewis肺癌小鼠皮下移植瘤模型16只,按随机数字法分为IL-18治疗组、荷瘤模型组,每组8只,分别给予IL-18、生理盐水于接种第7日起腹腔注射。观察IL-18对移植瘤体积变化及瘤重的影响。结果:IL-18对小鼠健康状况无明显影响,但对小鼠移植瘤生长有明显抑制作用,肿瘤抑制率为75%。结论:IL-18可抑制Lewis肺癌小鼠移植瘤的生长,其机制值得深入研究。  相似文献   

7.
目的 研究脱毒清肺胶囊对昆明种小鼠机体免疫功能。移植肿瘤生长以及对人肺癌SPC—A—1细胞株的影响。方法 对肺癌进行了扶正抗癌的实验研究。结果 该药可使荷瘤小鼠脾和胸腺细胞摄入~3H—TdR能力增强,对移植瘤有抑制作用,体外实验对人SPC—A—1有明显的细胞毒作用。结论 证明其抑瘤机理与提高机体免疫力有关。  相似文献   

8.
蛞蝓糖蛋白提出多糖对肺腺癌作用的实验研究   总被引:1,自引:0,他引:1  
目的:探讨蛞蝓糖蛋白提出多糖(LE—DZ)在体内外对肺腺癌的抑制作用。方法:细胞计数法检测LE—DZ对人肺腺癌A549细胞生长增殖的抑制作用,并绘制细胞生长曲线;平板克隆实验测定细胞集落形成率;建立小鼠Lewis肺癌模型,测皮下移植瘤体积绘制体积生长曲线,测移植瘤重量,计数小鼠肺表面转移结节数,并计算出抑瘤率和肺转移抑制率;光镜和电镜观察肿瘤组织病理变化。结果:在体外,1、10、100μg/ml浓度LE-DZ均能抑制人肺腺癌A549细胞增殖,并呈浓度和时间依赖性;与对照组比较,细胞集落形成率明显下降(P〈0.05)。在体内,LE—DZ能够抑制小鼠Lewis肺癌移植瘤生长和自发性肺转移,25、50、100μg/ml浓度LE—DZ瘤重抑制率分别为19.65%、39.81%、50.96%,肺转移抑制率分别为23.08%、43.27%、68.27%,且呈浓度依赖性。病理学观察结果,LE—DZ可引起肿瘤细胞坏死,诱导肿瘤细胞凋亡。结论:LE—DZ在体外能抑制肺腺癌A549细胞增殖,在体内能抑制小鼠Lewis肺癌皮下移植瘤生长和自发性肺转移,并诱导癌细胞凋亡。  相似文献   

9.
 目的 探讨IL-18对Lewis肺癌小鼠移植瘤生长及移植瘤细胞凋亡的作用。 方法 复制Lewis肺癌小鼠模型16只,随机分为IL-18治疗组与荷瘤模型组,每组8只,分别予IL-18、生理盐水于接种第7日起每日1次腹腔注射,连续7次。观察IL-18对小鼠健康状况、移植瘤变化的影响,并用TUNEL方法检测其对移植瘤细胞凋亡的作用。 结果 IL-18对小鼠健康状况无明显影响, 对移植瘤的生长有抑制作用,肿瘤抑制率为75%,对移植瘤细胞的凋亡有促进作用。 结论 IL-18可通过促进肿瘤细胞凋亡等途径对Lewis肺癌产生抑制作用,有望成为肺癌治疗的新策略。  相似文献   

10.
 目的 观察SA脂质体介导血管抑素和/或内皮抑素基因对Lewis肺癌小鼠移植瘤生长、转移的抑制作用。方法 建立C57BL/6j小鼠肺癌模型,30只荷瘤鼠随机分空白对照组,SA脂质体对照组,血管抑素基因(pAng)治疗组,内皮抑素基因(pEnd)治疗组,血管抑素和内皮抑素基因联合治疗组,每组6只。以SA脂质体介导,将血管抑素和/或内皮抑素基因直接注入移植瘤内,每周2次,共6周,每周测瘤体大小2次,6周末处死所有小鼠,观察瘤体大小变化、肺表面转移灶数、生存期等。结果 各治疗组均能抑制肿瘤增长及肺内转移,与对照组比较有统计学意义(P<0.01),小鼠活动能力、饮食、对外界刺激的反应能力均无明显改变,生存期明显长于对照组。结论 SA脂质体介导血管抑素和/或内皮抑素基因治疗可有效地抑制Lewis肺癌移植瘤的生长、转移,生存期明显长于对照组。  相似文献   

11.
目的:评价噬菌体展示肽GX1与胃癌新生血管结合的特异性及体内靶向性。方法:化学合成Bio-GX1展示肽;构建人胃癌移植瘤裸鼠模型,A组将Bio-GX1展示肽经尾静脉注入荷瘤小鼠体内,分别于体内循环8h、12h、18h、24h时处死裸鼠,B组将GX1噬菌体经尾静脉注入荷瘤小鼠体内,于体内循环8min时处死裸鼠,免疫荧光方法检测GX1噬菌体及展示肽与胃癌血管体内结合特异性及靶向性;构建小鼠肾包膜下胃癌移植瘤模型,分别于移植瘤术后第5天、第10天经尾静脉注入Bio-GX1展示肽,体内循环8h处死小鼠,免疫荧光方法检测GX1与胃癌血管体内结合的特异性及靶向性。结果:GX1展示肽体内循环8-24h,GX1噬菌体体内循环8min,可特异靶向人胃癌移植瘤裸鼠胃癌组织血管,而与肝、心、脾、肾(脑)、肺、肌肉组织等对照组织血管未见明显结合;GX1展示肽体内循环8h,可特异靶向小鼠肾包膜下胃癌移植瘤模型肿瘤血管,与对照组织血管未见明显结合。结论:GX1噬菌体及展示肽均可在体内特异靶向胃癌血管,具有体内胃癌血管靶向性,可作为胃癌血管靶向治疗及诊断的有效候选分子。  相似文献   

12.
Experimental chemotherapy with UFT was performed against human urogenital cancers, transplanted subcutaneously and under the subrenal capsule (SRC) of nude mice. The tumor take with subcutaneous assay was confirmed in 21 cell lines of human neoplasms, which consisted of 9 renal cell carcinomas, 5 renal pelvic carcinomas, 1 ureteral carcinoma, 3 carcinomas of the urinary bladder, 2 prostatic carcinomas and 1 testicular tumor. On the other hand, the tumor take with subrenal capsule assay was confirmed in 17 of the neoplasm, which consisted of 7 renal cell carcinomas, 4 renal pelvic carcinomas, 4 carcinomas of urinary bladder, 1 prostatic carcinoma and 1 testicular tumor. UFT was administered, starting on Day 14 for subcutaneous transplantation and starting on Day 0 for SRC assay. The dose of UFT was the same as clinical dose for both subcutaneous transplantation and subrenal capsule assays. Treatment with UFT was performed for 6 weeks in subcutaneous transplantation assay and for 4 weeks in subrenal capsule assay. Effect of UFT was evaluated by the inhibition rate (IR) calculated by the mean tumor weights of both treated and untreated groups. Responses to the treatment in subcutaneous transplantation and subrenal capsule assays were judged as effective when the IR were higher than 58% and 20%, respectively. Responses rates of UFT in subcutaneous transplantation and subrenal capsule assays were 43% and 82%, respectively.  相似文献   

13.
To develop a reproducible in vivo model for the growth of human acoustic neuromas and neurofibromas, we implanted tumor specimens (6 acoustic neuromas; 4 neurofibromas; 3 schwannomas arising in skin and soft tissues) from 13 different patients into the subrenal capsules of 67 nude mice and sciatic nerves of 64 nude mide. The animals were anesthetized and the tumors were microscopically implanted. Serial tumor volumes were determined at intervals up to 2 months by reopening the incision and directly measuring the tumor size with a micrometer. The percentages of acoustic neuromas that survived or grew were 57.1% in the subrenal capsule and 88.9% in the sciatic nerves; the percentages of neurofibromas that survived and grew were 50% in the subrenal capsule and 70% in the sciatic nerves; and the percentages of schwannomas that survived and grew were 57.1% in the subrenal capsule and 94.1% in the sciatic nerve. Tumors in the sciatic nerve also survived and grew for a longer period than those in the subrenal capsules. Tumor enlargement and stability correlated with neovascularity. At 1 or 2 months after engraftment, the tumors showed histologic appearances similar to the original tumors and immunohistochemical analysis of cryostat sections demonstrated staining of the tumors, but not the host mouse tissues for human 2-microglobulin, a species-specific marker. Furthermore, analysis of genomic DNA from implanted tumors revealed its human origin. We conclude that human acoustic neuromas, neurofibromas and schwannomas are readily grown in two sites in nude mice and that they retain their morphologic features and genomic identities. These tumors grow better and more consistently in the sciatic nerve than in the subrenal capsule. These are useful model systems for studying tumor growth and cellular modulation.  相似文献   

14.
The antitumor activity of 27 anticancer drugs against a human breast cancer tumor (MX-1) has been studied using the subrenal capsule assay developed by A.E. Bogden et al. in 1978. Without immunosuppression with cyclophosphamide, BDF1 mice transplanted with MX-1 were treated with various drugs. The antitumor activity was evaluated by the tumor growth inhibition rate on day 6 after treatment. Among the 27 anticancer drugs tested, 10 compounds (37%) which showed more than 75% tumor growth inhibition rate were considered to be active. On the other hand, 8 compounds out of 27 drugs (30%) which showed less than 50% tumor growth inhibition rate were considered to be inactive. When the antitumor activity between the subrenal capsule assay in BDF1 mice and the subcutaneous transplantation assay in nude mice were compared, both assays were well correlated (r = 0.787, p less than 0.001). These results suggest that the antitumor activity of drugs can be evaluated faster, cheaper and easier by the subrenal capsule assay compared with the subcutaneous transplantation assay in nude mice.  相似文献   

15.
金荞麦提取物治疗肺癌的临床前预测研究   总被引:6,自引:0,他引:6  
本文利用小鼠、肾囊膜下移植法(SRCA)预测评价了金荞麦提取物金E和CD_1对12例肺癌组织块异种移植后治疗的敏感性,初步观察了两种提取物对荷瘤宿主的毒副作用。移植实验总可评价率为83.3%(10/12)。以移植前后癌组织体积改变OMU<-10为有效标准,金E和CD_1的有效比分别为4/10和2/10。肺鳞癌对金E治疗的敏感性高于其它组织类型的肺癌。两种提取物时宿主无明显毒副反应。利用SRCA法进行临床前期预测评价有苗头的抗癌剂尚属新的尝试。  相似文献   

16.
Wen ZS  Zhang TJ  Rong TH 《癌症》2003,22(12):1355-1358
背景与目的:化学药物治疗(化疗)是非小细胞肺癌(non-smallcelllungcancer,NSCLC)综合治疗主要措施之一,传统的化疗方案尽管能取得短期疗效,但与单纯手术治疗相比,对患者的生存期无明显提高。本研究旨在通过非小细胞肺癌裸鼠体内肿瘤药物筛选,进行有针对性的个体化药物治疗,希望借此能提高患者的生存期。方法:非小细胞肺癌组织块植入裸鼠双侧肾包膜下,选用10种常用治疗非小细胞肺癌药物进行敏感药物筛选。130例非小细胞肺癌患者术后分成临床实验组(GroupⅠ,70例)和临床对照组(GroupC,60例)两组。临床实验组依据肿瘤药敏结果进行术后辅助化疗,临床对照组选择传统化疗方案(CTX:600mg/m2d1、ADM:40mg/m2d1、DDP:20mg/m2d1~5)辅助化疗。结果:临床实验组与临床对照组比较,无论是肿瘤局部复发率(43.1%vs46.0%,P=0.556)、远处转移率(33.8%vs34.0%,P=0.605)还是5年生存率(35.4%vs34.0%,P=0.571),两组差异均无统计学意义(P>0.05)。结论:裸鼠肾包膜下药敏实验对非小细胞肺癌术后辅助化疗无明显临床应用价值。  相似文献   

17.
PURPOSE: Lung cancer is a biologically diverse disease and relevant models reflecting its diversity would facilitate the improvement of existing therapies. With a view to establishing such models, we developed and evaluated xenografts of a variety of human lung cancers. EXPERIMENTAL DESIGN: Using nonobese diabetic/severe combined immunodeficiency mice, subrenal capsule xenografts were generated from primary lung cancer tissue, including moderately and poorly differentiated squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, large cell undifferentiated carcinoma, and carcinosarcoma. After 4 to 12 weeks, xenografts were harvested for serial transplantation and comparison with the original tissue via histologic, chromosomal, and cytogenetic analyses. RESULTS: Xenografts were successfully established. H&E staining showed that xenografts retained major histologic features of the original cancers. Immunohistochemistry and fluorescence in situ hybridization confirmed the human origin of the tumor cells and development in xenografts of murine supportive stroma. Four transplantable lines were developed from rapidly growing tumors (>5 generations), i.e., a small cell lung carcinoma, large cell undifferentiated carcinoma, pulmonary carcinosarcoma, and squamous cell carcinoma. Analyses including spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization, revealed that the xenografts were genetically similar to the original tumors, showing chromosomal abnormalities consistent with karyotypic changes reported for lung cancer. CONCLUSIONS: The subrenal capsule xenograft approach essentially provides a living tumor bank derived from patient material and a means for isolating and expanding specific cell populations. The transplantable tumor lines seem to provide good models for studying various aspects of tumor progression and a platform for developing novel therapeutic regimens, with the possibility of patient-tailored therapies.  相似文献   

18.
[目的]观察胃癌肾包膜下移植瘤模型是否适用于血管生成方面的研究.[方法]建立昆明种小鼠癌细胞接种的肾包膜下移植瘤模型后饲养6天,处死.PAS染色证实肿瘤细胞存活,通过HE染色及免疫组化法观察种植肿瘤区域有无血管生成.[结果]实验动物全部存活,PAS染色表明模型建立成功,肿瘤种植区域无血管生成.[结论]使用癌细胞接种的肾包膜下移植瘤模型较适用于研究癌细胞的分化与凋亡,不适于新生血管生成的研究.  相似文献   

19.
Using tumor specimens of human cancer serially transplanted in nude mice, we examined fundamentally the subrenal capsule assay method in order to improve the subrenal space as an area where implanted tumor-xenografts persistently grow. Host reaction in immunocompetent mice treated with cyclosporin A (CsA) (60 mg/kg subcutaneously, daily) was suppressed almost completely, and tumor-xenografts persistently grew similarly to those implanted under the renal capsule of BALB/c-nu/nu mice. CsA treatment, 30 mg/kg given subcutaneously; daily, or 60 mg/kg subcutaneously; every other day, could not suppress the host reaction. Bredinin treatment, 200 mg/kg subcutaneously; every other day, or 100 mg/kg subcutaneously; daily, could not suppress the host reaction also, and tumor-xenografts implanted under the renal capsule were rejected.  相似文献   

20.
Penclomedine, a synthetic alpha-picoline derivative, was identified as a potential antitumor agent in the P388 leukemia prescreen of the National Cancer Institute. Upon further evaluation in the National Cancer Institute in vivo tumor panel, the compound demonstrated good activity against two breast tumors. A single i.p. dose or five daily doses caused partial regressions of advanced-stage s.c. implanted mouse CD8F1 mammary adenocarcinomas. Also, penclomedine administered i.p. on Days 1,5, and 9 caused regression of the human MX-1 mammary carcinoma implanted under the renal capsule of athymic mice. In contrast, penclomedine demonstrated only marginal to moderate activity against the i.p. implanted L1210 leukemia and M5076 sarcoma and was inactive in three additional non-breast tumor models (i.p. B16 melanoma, i.v. Lewis lung carcinoma, and s.c. colon adenocarcinoma 38). Penclomedine administered p.o. and i.p. was equally effective against the subrenal capsule MX-1. Doses given p.o. every fourth day caused complete regression of 39 of 40 advanced-stage s.c. implanted MX-1 tumors but were much less effective against human H82 small cell lung carcinomas (13 of 80 complete regressions). Penclomedine p.o. also inhibited growth of the human MCF-7 and mouse 16/C breast adenocarcinomas. Further studies to support the development of penclomedine to clinical trial are in progress.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号